Track Mind Medicine (MindMed) Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Mind Medicine (MindMed) Inc. DFTX · Stock Open Mind Medicine (MindMed) Inc. in new tab

32.08 USD
EPS
-2.92
P/B
4.54
ROE
-61.44
Beta
2.21
Target Price
72.78 USD
Mind Medicine (MindMed) Inc. logo

Mind Medicine (MindMed) Inc.

🧾 Earnings Recap – Q3 2026

Definium shares fell 2.1% after the earnings call, a roughly flat reaction. The update included positive Phase 3 findings and regulatory progress, but the next major MDD readout remains ahead: ASCEND top-line data are expected in 2027.

  • In VOYAGE, a single 100-microgram dose produced a 5.4-point placebo-adjusted improvement on the HAM-A at week 12 (p<0.0001); the 214-participant study met its primary and all key secondary endpoints.
  • In PANORAMA, the same dose produced a 5.1-point placebo-adjusted HAM-A improvement at week 12 (p<0.0001); the 245-participant study also met its primary and all key secondary endpoints.
  • Management said DT-120 was generally well tolerated in the completed double-blind phases of three studies, with no drug-related serious adverse events or suicidality signal; dosing sessions averaged about six hours.
  • The company is targeting an NDA filing in the first half of 2027. ASCEND, its second Phase 3 MDD study, is enrolling, with top-line data expected in 2027.
  • DT-120 has received two FDA breakthrough therapy designations, for GAD and MDD; the company also reported encouraging initial DT-402 signals in an open-label Phase 2a study in adults with autism spectrum disorder.
📅
Loading chart...
Key Metrics
Earnings dateMarch 11, 2027
EPS-2.92
Book Value7.07
Price to Book4.54
Debt/Equity3.79
% Insiders3.195%
Estimates
Forward P/E-16.50
Forward EPS-1.94
Target Mean Price72.78

DCF valuation

Model fair value for Mind Medicine (MindMed) Inc. (DFTX)
Result
Sign in to run the valuation for DFTX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
18 analysts · consensus Strong buy · mean target 72.78 USD (low 55.00, high 91.00) · as of 15 Nov 2026
Low 55.00
Mean 72.78
High 91.00
Price 32.08
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Mind Medicine (MindMed) Inc. Logo Mind Medicine (MindMed) Inc. Analysis (DFTX)

Is Mind Medicine (MindMed) Inc. a good investment? Mind Medicine (MindMed) Inc. (DFTX) is currently trading at 32.08 USD. Market analysts have a consensus price target of 72.78 USD. This suggests a potential upside from current levels.

Earnings Schedule: Mind Medicine (MindMed) Inc. is expected to release its next earnings report on March 11, 2027. The market consensus estimate for Forward EPS is -1.94.

Investor FAQ

Does Mind Medicine (MindMed) Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Mind Medicine (MindMed) Inc.?

Mind Medicine (MindMed) Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 11, 2027. The company currently has a trailing EPS of -2.92.

Company Profile

Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.

Exchange Ticker
DFTX
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Aug. 29, 2022 1:15
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion